Showing posts with label Dihydroergotamine. Show all posts
Showing posts with label Dihydroergotamine. Show all posts

Friday, May 27, 2011

MAP Pharmaceuticals submits LEVADEX NDA to FDA for treatment of migraine in adults


Levadex is designed to be differentiated from existing migraine treatments. It is a novel formulation of dihydroergotamine (see above structure, DHE), a drug used intravenously in clinical settings to effectively and safely treat migraines.
 MAP Pharmaceuticals submits LEVADEX NDA to FDA for treatment of migraine in adults